UP!

WBA $17.59

WBA target price
17.59
32
54
Walgreens Boots Alliance, Inc.
Type
Public
Traded as NASDAQ: WBA
NASDAQ-100 Component
S&P 100 Component
S&P 500 Component
Industry Pharmaceutical
Retail
Founded Chicago, United States (December 31, 2014 (December 31, 2014))
Founders Charles Rudolph Walgreen
Walgreens (1901)
John Boot
Boots (1849)
Headquarters Deerfield, Illinois, United States
Area served
Worldwide
Key people
Jim Skinner
(Executive Chairman)
Stefano Pessina
(Vice Chairman and CEO)
Products Drug store
Pharmacy
Revenue IncreaseUS$117.35 billion (2016)
Operating income
IncreaseUS$6.001 billion (2016)
Net income
IncreaseUS$4.173 billion (2016)
Total assets IncreaseUS$72.68 billion (2016)
Total equity IncreaseUS$30.28 billion (2016)
Number of employees
400,000 (2016)
Divisions Retail Pharmacy USA
Retail Pharmacy International
Pharmaceutical Wholesale
Subsidiaries Alliance Healthcare
Boots UK
Boots Opticians
Duane Reade
drugstore.com
Walgreens
Farmacias Benavides
Farmacias Ahumada
Website walgreensbootsalliance.com

Walgreens Boots Alliance, Inc. is an American holding company headquartered in Deerfield, Illinois that owns Walgreens, Boots and a number of pharmaceutical manufacturing, wholesale and distribution companies. The company was formed on December 31, 2014 after Walgreens purchased the 55% stake in Switzerland-based Alliance Boots that it did not already own. Walgreens had previously purchased 45% of the company in 2012 with an option to purchase the remaining shares within three years.

Under the terms of the merger, the new company was organized into three divisions: Retail Pharmacy USA (Walgreens), Retail Pharmacy International (Boots), and Pharmaceutical Wholesale, incorporating Alliance Healthcare. The new holding company began trading on the NASDAQ on December 31, 2014.

The combined business has operations in over 25 countries. Walgreens had formerly operated solely within the United States and its territories, while Alliance Boots operated a more international business.

In October 2016, Walgreens Boots Alliance published its fourth quarter earnings report. Fiscal year 2016 totaled sales were $117.35 billion, up 13.4% from $103.44 in fiscal 2015, and GAAP net earnings decreased to $4.17 billion.

Walgreens and Duane Reade operate within the Retail Pharmacy USA division of Walgreens Boots Alliance. Both businesses sell prescription and non-prescription drugs, and a range of household items, including personal care and beauty products. Walgreens provides access to consumer goods and services, plus pharmacy, photo studio, health and wellness services in the United States through its retail drugstores. Walgreens had 8,230 drugstores as of December 2015. Walgreens runs several online stores, such as: Beauty.com, Drugstore.com and VisionDirect.com.

Walgreens has stores in all 50 US states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands.

On October 27, 2015, Walgreens announced the purchase of competitor Rite Aid for $17.2 billion.

On September 19, 2017, the Federal Trade Commission (FTC) approved a fourth deal agreement to purchase Rite Aid with 1,932 stores for $4.38 billion total.

Boots forms the main part of the Retail Pharmacy International division of the company. The Boots brand has a history stretching back over 160 years and is a familiar sight on Britain's high streets. Stores are located in prominent high street and city center locations as well as in local communities. Most branches include a pharmacy and focus on healthcare, personal care and cosmetic products, with most stores selling over the counter medicines. Larger stores typically offer a variety of healthcare services in addition to dispensing prescriptions, and chlamydia testing & treatment (private service). Optician services are also offered in many larger stores, with Boots Opticians providing eye tests along with the sale of spectacles and contact lenses.

Many stores also feature traditional photo processing and/or a HP picture kiosk where users of digital cameras and camera phones can create prints via Bluetooth, USB or CD. Larger stores usually offer a range of electrical equipment such as hairdryers, curlers and foot massagers, whilst selected stores offer a range of sandwiches, baguettes, wraps, salads and beverages.

Since 1936, there have been Boots stores outside the UK. Stores in countries as widely spread as New Zealand, Canada (see Pharma Plus) and France were all closed in the 1980s. Today, there are Boots branded stores outside the UK and Ireland in countries including United Arab Emirates, Bahrain, Norway, Lithuania, The Netherlands, and Thailand.

The remainder of the division is made up of the pharmacies Benavides in Mexico and Farmacias Ahumada (FASA) in Chile.

Alliance Healthcare forms the main part of Walgreens Boots Alliance's Pharmaceutical Wholesale division. It operates twice daily deliveries to more than 16,000 delivery points in the UK alone. Internationally, Alliance Healthcare supplies medicines, other healthcare products and related services to over 200,000 pharmacies, doctors, health centers and hospitals from over 350 distribution centers in 19 countries.

In addition to the wholesale of medicines and other healthcare products, Alliance Healthcare provides services to pharmaceutical manufacturers who are increasingly changing and adapting their approaches to distribution, while at the same time outsourcing non-core activities. These services include pre-wholesale and contract logistics, direct deliveries to pharmacies, and specialized medicine delivery including related home healthcare.

The division's Alphega Pharmacy network provides a range of services for independent pharmacies, including branding, professional training and patient care, retail support services and supply benefits together with pharmacy and IT support.

Boots produces a large number of brands that Alliance Boots and Walgreens sought to launch internationally following the first share purchase in 2012. The majority are produced by its subsidiary, BCM Limited, which manufactures both own-brand and third-party medicines, as well as cosmetic ranges including No 7, Kangol, FCUK, Soltan, and Botanics. BCM has facilities in the UK, Germany, and France. BCM Specials manufactures bespoke non-licensed medicines for UK hospital and retail pharmacies.

Launched in 1935, No7 is best known for its anti-aging beauty serums, developed in Nottingham that first appeared in 2007. The range comprises products designed to target the aging concerns of specific age groups. No7 became available in Walgreens and Duane Reade stores in the USA from November 2012, beginning in Los Angeles.

Launched in 1939, Soltan markets its UVA 5-star protection, a standard of protection developed by Boots and now adopted as the benchmark for suncare products in the UK. Although in both 2004 and 2015 Watchdog, a BBC consumer investigative TV program, and cited on BBC News; plus the consumer WHICH? Magazine, each did an investigation finding the 5-star rating was unsubstantiated, and skincare experts declared it to be far less safe than claimed.

First launched in 1995, the Botanics range, developed in partnership with the Royal Botanic Gardens, Kew, uses plant extracts in a variety of products, and includes a range of organic products. The Botanics range is also available through third party retailers.

The Boots own brand range of products includes skincare, medicines, healthcare products and many more. Boots Laboratories skincare range for independent pharmacy customers was launched in France and Portugal in 2008/09and is also sold in Spain, Italy and Germany.

Boots launched Almus, a brand of generic prescription drugs, in the UK in 2003. It is now sold in five countries and is an umbrella brand for a wide range of lower cost generic medicines. Alliance Boots placed considerable emphasis on the design of the packaging in an attempt to reduce the number of errors by the dispensing chemist and by the patient relating to incorrect dosage which can result in either a dangerous accidental overdose or an equally dangerous under dose.

Walgreens has a self-branded line of products, "Well at Walgreens".

In 2015, Walgreens Boots Alliance paid £140 million (about $250 million) for UK skincare brand Liz Earle Naturally Active, an Avon subsidiary since 2010. Liz Earle Beauty Co co-founder Liz Earle, 'one of the biggest names in the beauty industry' stayed on as an 'ambassador' after selling the company for an undisclosed sum and told her own Liz Earle Wellbeing magazine's website that '...alongside my new digital and print publishing venture...at the moment I’m still connected to Liz Earle Beauty Co and continue to work as a consultant to the brand that carries my name. I’m involved in new product development...'

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q2 2023 2023-06-29 Future report Set alerts
Q1 2023 2023-01-05 1.16 1.16
Q4 2022 2022-10-13 0.80 0.80
Q3 2022 2022-06-30 0.96 0.96
Q2 2022 2022-03-31 1.59 1.59
Q1 2022 2022-01-06 1.68 1.68
Q4 2021 2021-10-14 1.17 1.17
Q3 2021 2021-07-01 1.38 1.38
Q2 2021 2021-03-31 1.26 1.26
Q1 2021 2021-01-07 1.22 1.22

Ratings

2016-07-07 Boost Price Target Barclays PLC Equal Weight $76.00 to $79.00
2016-07-07 Reiterated Rating Jefferies Group Hold to Neutral
2016-07-07 Lower Price Target FBR & Co Market Perform $90.00 to $85.00
2016-07-07 Reiterated Rating Evercore ISI Buy $93.00
2016-07-07 Reiterated Rating JPMorgan Chase & Co. Buy
2016-06-27 Reiterated Rating Robert W. Baird Outperform $98.00
2016-06-13 Reiterated Rating Bank of America Buy
2016-06-13 Reiterated Rating Bank of America Corp. Buy
2016-06-10 Reiterated Rating Deutsche Bank Buy
2016-06-10 Reiterated Rating Deutsche Bank AG Buy
2016-06-07 Reiterated Rating Bank of America Buy $94.00 to $78.66
2016-04-19 Reiterated Rating Jefferies Group Hold
2016-04-11 Reiterated Rating Leerink Swann Buy $95.00
2016-04-07 Reiterated Rating Credit Suisse Buy $95.00
2016-04-07 Reiterated Rating Credit Suisse Group AG Buy $95.00
2016-04-06 Reiterated Rating Evercore ISI Buy $95.00
2016-04-05 Boost Price Target Evercore ISI Buy $94.00 to $95.00
2016-04-02 Reiterated Rating Deutsche Bank Buy
2016-04-01 Reiterated Rating Morgan Stanley Buy $95.00
2016-03-19 Reiterated Rating Deutsche Bank Buy $95.00
2016-03-16 Initiated Coverage Credit Suisse Outperform Ratings
2016-03-15 Reiterated Rating Credit Suisse Outperform $100.00 to $92.00
2016-03-10 Lower Price Target Barclays Equal Weight $81.00 to $76.00
2016-03-10 Lower Price Target Barclays PLC Equal Weight $81.00 to $76.00
2016-03-01 Upgrade Mizuho Neutral to Buy $89.00 to $90.00
2016-02-12 Reiterated Rating FBR & Co. Market Perform
2016-02-12 Reiterated Rating FBR & Co Market Perform
2016-02-10 Reiterated Rating Deutsche Bank Buy
2016-02-06 Reiterated Rating Citigroup Inc. Buy $111.00 to $88.00
2016-02-03 Initiated Coverage Atlantic Securities Neutral $88.00
2016-01-21 Initiated Coverage Robert W. Baird Outperform $96.00
2016-01-10 Reiterated Rating FBR & Co. Market Perform $90.00
2016-01-08 Reiterated Rating Guggenheim Buy
2016-01-08 Reiterated Rating Leerink Swann Buy $105.00
2016-01-06 Reiterated Rating Deutsche Bank Buy $95.00
2016-01-06 Upgrade Evercore ISI Hold to Buy $94.50
2015-12-15 Reiterated Rating Jefferies Group Hold $95.00 to $90.00
2015-11-16 Reiterated Rating Leerink Swann Buy
2015-11-16 Upgrade Raymond James Market Perform to Outperform
2015-11-16 Lower Price Target Credit Suisse Outperform $110.00 to $100.00
2015-11-16 Upgrade Raymond James Financial Inc. Market Perform to Outperform
2015-10-30 Boost Price Target Scotiabank $100.00 to $101.00
2015-10-29 Reiterated Rating S&P Equity Research Buy $99.00
2015-10-29 Lower Price Target Barclays Equal Weight $86.00 to $81.00
2015-10-28 Reiterated Rating Cowen and Company Buy $102.00
2015-10-28 Upgrade RBC Capital Hold to Buy $98.00 to $103.00
2015-10-28 Boost Price Target Jefferies Group Hold $90.00 to $105.00
2015-10-28 Upgrade Royal Bank Of Canada Hold to Buy $98.00 to $103.00
2015-10-21 Lower Price Target Cowen and Company $104.00 to $102.00
2015-09-09 Upgrade Cowen and Company Market Perform to Outperform $90.00 to $104.00
2015-07-16 Upgrade Credit Suisse Neutral to Outperform $90.00 to $110.00
2015-07-15 Reiterated Rating Citigroup Inc. Buy $107.00 to $111.00
2015-07-11 Reiterated Rating Macquarie Buy
2015-07-10 Reiterated Rating FBR & Co. Hold
2015-07-10 Reiterated Rating Macquarie Outperform $95.00 to $100.00
2015-07-10 Reiterated Rating Deutsche Bank Buy $89.00 to $95.00
2015-07-10 Reiterated Rating Barclays Hold $81.00 to $86.00
2015-07-10 Upgrade RBC Capital Sector Perform to Outperform
2015-07-10 Upgrade Raymond James Market Perform to Outperform
2015-07-10 Boost Price Target Leerink Swann Outperform $95.00 to $109.00
2015-07-10 Reiterated Rating Mizuho Neutral $86.00 to $89.00
2015-07-09 Boost Price Target Evercore ISI Hold $94.00 to $95.00
2015-07-09 Reiterated Rating William Blair Outperform
2015-07-09 Boost Price Target FBR & Co. Market Perform $80.00 to $90.00
2015-06-30 Boost Price Target Leerink Swann Outperform $85.00 to $95.00
2015-06-09 Initiated Coverage Macquarie Outperform $95.00
2015-05-22 Upgrade Tigress Financial Underperform to Neutral
2015-04-16 Boost Price Target Jefferies Group Hold $82.00 to $90.00
2015-04-13 Boost Price Target Citigroup Inc. Buy $88.00 to $107.00
2015-04-12 Reiterated Rating Deutsche Bank Buy $89.00
2015-04-08 Boost Price Target Mizuho Neutral $72.00 to $86.00
2015-04-02 Set Price Target Morgan Stanley Buy $91.00
2015-03-19 Boost Price Target Deutsche Bank Buy $82.00 to $89.00
2015-03-06 Set Price Target Credit Suisse Hold $85.00
2015-01-23 Set Price Target Deutsche Bank Buy $82.00
2015-01-13 Downgrade Jefferies Group Buy to Hold $67.00 to $82.00
2015-01-05 Reiterated Rating Deutsche Bank Buy $82.00
2014-12-26 Boost Price Target Credit Suisse Neutral $68.00 to $73.00
2014-12-24 Boost Price Target JPMorgan Chase & Co. Overweight $70.00 to $88.00
2014-12-24 Boost Price Target Barclays Equal Weight $68.00 to $72.00
2014-12-24 Boost Price Target Leerink Swann Outperform $75.00 to $85.00
2014-12-24 Boost Price Target FBR & Co. Hold $70.00
2014-12-23 Reiterated Rating Bank of America Hold
2014-12-23 Set Price Target Deutsche Bank Buy $82.00
2014-12-19 Set Price Target Cantor Fitzgerald Hold $56.00
2014-12-19 Downgrade SunTrust Buy to Neutral $72.00 to $77.00
2014-12-19 Downgrade SunTrust Banks Inc. Buy to Neutral $72.00 to $77.00
2014-12-10 Initiated Coverage Citigroup Inc. Buy $80.00
2014-12-09 Downgrade Mizuho Buy to Neutral $83.00 to $72.00
2014-12-05 Boost Price Target Evercore ISI Hold $63.00 to $71.50
2014-12-03 Reiterated Rating Bank of America Neutral
2014-12-02 Reiterated Rating Morgan Stanley Overweight
2014-11-05 Reiterated Rating Tigress Financial Underperform
2014-10-06 Lower Price Target Deutsche Bank Buy $69.00 to $67.00
2014-10-01 Reiterated Rating Scotiabank Outperform
2014-10-01 Reiterated Rating JPMorgan Chase & Co. Overweight $71.00 to $70.00
2014-10-01 Reiterated Rating Morgan Stanley Overweight $77.00
2014-09-30 Lower Price Target FBR & Co. Market Perform $66.00 to $62.00
2014-09-22 Downgrade Barclays Overweight to Equal Weight $92.00 to $68.00
2014-09-04 Reiterated Rating Evercore ISI Neutral
2014-08-21 Upgrade Bank of America Underperform to Neutral $30.00 to $66.00
2014-08-12 Lower Price Target Deutsche Bank $69.00
2014-08-07 Lower Price Target BB&T Corp. Buy $80.00 to $65.00
2014-08-07 Reiterated Rating Cowen and Company Market Perform $74.00 to $62.00
2014-08-07 Reiterated Rating Jefferies Group Buy $87.00 to $69.00
2014-08-07 Upgrade Cantor Fitzgerald Sell to Hold $50.00 to $56.00
2014-08-06 Lower Price Target Evercore ISI Cautious $74.50 to $67.00
2014-06-26 Reiterated Rating Scotiabank Sector Outperform
2014-06-25 Reiterated Rating JPMorgan Chase & Co. Overweight $74.00 to $77.00
2014-06-25 Upgrade Morgan Stanley Hold to Overweight $69.00 to $85.00
2014-06-25 Lower Price Target Goldman Sachs $84.00
2014-06-25 Boost Price Target FBR & Co. Market Perform $68.00 to $73.00
2014-06-25 Upgrade Jefferies Group Hold to Buy $69.00 to $87.00
2014-06-25 Boost Price Target BB&T Corp. $72.00 to $80.00
2014-06-23 Boost Price Target Susquehanna Positive $80.00 to $95.00
2014-06-20 Boost Price Target SunTrust Buy $82.00 to $87.00
2014-06-18 Upgrade Barclays Equal Weight to Overweight $56.00 to $92.00
2014-06-09 Boost Price Target Mizuho Buy $78.00 to $83.00
2014-06-02 Reiterated Rating Morgan Stanley Overweight $75.00
2014-05-14 Downgrade Cowen and Company Outperform to Market Perform
2014-05-12 Reiterated Rating Morgan Stanley Positive to Overweight $75.00
2014-04-30 Reiterated Rating Jefferies Group Hold $62.00 to $69.00
2014-04-17 Boost Price Target Mizuho Buy $74.00 to $78.00
2014-04-15 Reiterated Rating Citigroup Inc. Positive to Overweight $75.00
2014-04-07 Boost Price Target Guggenheim $52.00 to $75.00
2014-03-27 Boost Price Target Morgan Stanley $68.00 to $75.00
2014-03-26 Boost Price Target Evercore ISI Neutral $69.00 to $70.00
2014-03-26 Boost Price Target BB&T Corp. $72.00
2014-03-26 Boost Price Target Cowen and Company $69.00 to $74.00
2014-03-26 Downgrade Macquarie Outperform to Neutral $64.00 to $68.00
2014-03-21 Boost Price Target SunTrust $70.00 to $77.00
2014-03-19 Reiterated Rating Morgan Stanley Overweight $68.00
2014-03-14 Boost Price Target Mizuho Buy $64.00 to $74.00
2014-03-12 Boost Price Target Goldman Sachs Buy $67.00 to $79.00
2014-03-04 Boost Price Target Susquehanna $67.00 to $80.00
2014-03-03 Reiterated Rating Morgan Stanley Hold to Overweight $68.00
2014-02-13 Reiterated Rating Morgan Stanley Overweight $68.00
2014-02-07 Initiated Coverage Leerink Swann Outperform to Outperform $68.00
2014-01-22 Upgrade Evercore ISI Cautious to Neutral $55.00 to $64.00
2013-12-30 Downgrade Ned Davis Research Buy to Neutral
2013-12-18 Reiterated Rating Morgan Stanley Overweight $70.00
2013-12-17 Lower Price Target Goldman Sachs Buy $68.00 to $67.00
2013-12-04 Boost Price Target Mizuho Buy $62.00 to $65.00
2013-11-20 Initiated Coverage Deutsche Bank Buy $73.00
2013-11-19 Downgrade Raymond James Outperform to Market Perform $62.00
2013-11-04 Boost Price Target BB&T Corp. Buy $62.00 to $67.00
2013-10-31 Boost Price Target Evercore ISI Neutral $65.00 to $69.50
2013-10-24 Initiated Coverage FBR & Co. Market Perform $62.00
2013-10-07 Initiated Coverage Jefferies Group Hold $62.00
2013-10-07 Upgrade Wolfe Research Underperform to Market Perform
2013-10-03 Boost Price Target Raymond James Outperform $55.00 to $62.00
2013-10-03 Boost Price Target Credit Suisse Neutral $45.00 to $55.00
2013-10-03 Upgrade Barrington Research Market Perform to Outperform $65.00
2013-10-02 Boost Price Target Cowen and Company Outperform $65.00
2013-10-02 Boost Price Target Citigroup Inc. Buy $63.00 to $64.00
2013-10-02 Boost Price Target BB&T Corp. Buy $59.00 to $62.00
2013-10-02 Boost Price Target Barclays Equal Weight $42.00 to $52.00
2013-10-01 Boost Price Target Goldman Sachs Buy $68.00
2013-09-30 Set Price Target Citigroup Inc. $57.00 to $63.00
2013-09-25 Boost Price Target Mizuho Buy $58.00 to $62.00
2013-09-23 Upgrade Morgan Stanley Equal Weight to Overweight $70.00
2016-07-07 Boost Price Target Barclays PLC Equal Weight $76.00 to $79.00
2016-07-07 Reiterated Rating Jefferies Group Hold to Neutral
2016-07-07 Lower Price Target FBR & Co Market Perform $90.00 to $85.00
2016-07-07 Reiterated Rating Evercore ISI Buy $93.00
2016-07-07 Reiterated Rating JPMorgan Chase & Co. Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks